US Personalized Medicine Market Size Likely to Grow at a CAGR of 17.32% By 2034

Market Size and Growth

As per the US Personalized Medicine Market size analysis conducted by the CMI team, the US personalized medicine market is expected to record a CAGR of 17.32% from 2025 to 2034. In 2025, the market size was USD 66.13 Billion. By 2034, the valuation is anticipated to reach USD 252.93 Billion.

Overview

As per the industry experts at CMI, the U.S. personalized medicine market is poised to witness a whopping CAGR in the forecast period. This could be attributed to genomic advancements such as next-generation sequencing that facilitate more accurate diagnostics and targeted therapies. The patients are asking for more customized approaches toward healthcare, thereby resulting in higher adoption of personalized medicine. Rise in incidences of chronic diseases such as cardiovascular diseases, cancer, and diabetes is accelerating the requirement of more personalized and effective treatment strategies. Conducive government policies coupled with raised funding for research and development activities are driving innovation.

Key Trends & Drivers

• Technological Advancements and Higher Healthcare Spending to Spell Growth: Continuous advancements in data analytics, genomics, and bioinformatics are pushing the U.S. personalized medicine market forward. technologies such as CRISPR, NGS, and AI are transformingtreatment plans and diagnostics and making them more targeted as well as individualized. This innovation translates into patients’ better understanding and customizes the treatment with better results. Also, as healthcare spending increases, the government as well as private agencies continue spending more dollars on the new technologies pertaining to modern medicine as mentioned above.

• Rise in Incidences of Chronic Diseases to Catalyze the U.S. Personalized Medicine Market: Chronic ailments cover conditions such as diabetes, cancer, and cardiovascular ailments. Personalized medicines are capable of being more effective in comparison with conventional types of treatment as they end up targeting the molecular and genetic basis of the conditions they address.

Report Scope

SWOT Analysis

• Strengths: Genomic medicine is getting included in clinical practice. It is playing a vital role in diagnosing as well as treating the disease, thereby offering precise, individualized treatments providing better outcomes. Also, institutions are sharing data concerning clinical background, genetic information, and lifestyles across the providers, which facilitates the provision of more extensive and individualized treatment options, thereby helping to release new drugs in a faster way.

• Weaknesses: Tailored treatments such as sequencing, genetic tests, and targeted medications are costlier in comparison with conventional treatments. This factor does act as a substantial barrier to healthcare systems and insurance firms. Also, handling sensitive data does raise legal and ethical challenges pertaining to data privacy and security. These are some of the threats to the U.S. personalized medicine market.

• Opportunities: Amalgamating personalized medicine with digital health technologies such as remote monitoring and wearable devices is anticipated to improve patient engagement as well as treatment outcomes. Personalized medicine can also help in the identification of disease risks and promotion of preventive measures. Strategic partnerships amongst research organizations, academic institutions, and industry players have the ability to accelerate the adoption and development of personalized medicine.

• Threats: Lengthy processes of approvals and complicated regulatory requirements for personalized medicine products are likely to delay market access. The market players are bound to lose interest by the time the entire course of treatment or drugs gets approved and goes live. These are the major threats to the U.S. personalized medicine market.

List of the prominent players in the US Personalized Medicine Market:

• Illumina Inc.
• Precision Biologics
• Danaher Corporation (Cepheid Inc.)
• GE HealthCare
• Celera Diagnostics LLC
• Decode Genetics Inc.
• Exact Sciences Corporation
• IBM Corporation
• Exagen Inc.
• Biogen
• QIAGEN
• Genentech Inc.
• 23andMe Inc.
• Asuragen Inc.
• Others

The US Personalized Medicine Market is segmented as follows:

By Product

• Personalized Medicine Diagnostics
• Personalized Medicine Therapeutics
• Personalized Nutrition and Wellness

By Application

• Oncology
• CNS
• Immunology
• Respiratory
• Liver
• Rheumatology

By Technology

• Big Data Analytics
• Artificial Intelligence
• Bioinformatics
• Gene Sequencing
• Drug Discovery
• Companion Diagnostics
• Genetics
• Liquid Biopsy
• Others (Predictive Modeling, Imaging)

By End-user

• Hospitals
• Diagnostic Centers
• Research & Academic Institutes